B+
Bull case
20%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
SLDB
Solid BiosciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Constructive FDA guidance could clarify an accelerated path for SGT-003 while the Phase 3 IMPACT DUCHENNE trial advances. Solid reported 53 INSPIRE participants dosed by August 4 and $377.7 million of cash and available-for-sale securities at June 30, with management projecting runway into mid-2028.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-02.
What can break
Early biomarker and tolerability observations may not translate into durable clinical benefit or Phase 3 success. [#IR-2026-08-06]
Momentum
7
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.20 · Bull $9.50 · Bear $2.50Analysis 2026-10-17; returns require an exact persisted reference.
Earnings
2026-11-02
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $18.71
Why
Momentum7 · Δ7d +0.5
Value41 · Δ7d -0.0
Sentiment45 · Δ7d -8.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-02.
- • Sentiment remains the lead driver in the composite, 7D delta -8.3.
Contradictions & invalidation
- • Early biomarker and tolerability observations may not translate into durable clinical benefit or Phase 3 success. [#IR-2026-08-06]
- • Enrollment, site activation, manufacturing or safety issues could delay SGT-003, SGT-212 or SGT-501 milestones. [#IR-2026-08-06]
- • The SGT-003 investment case remains dependent on clinical outcomes and FDA feedback.
Catalyst clock
2026-11-02
SGT-003 FDA discussion
Lead driver: Sentiment · See AI snapshot
Momentum
7
8% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
-4.2
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
45
45% active weight
Current posture
7d trendSoftening
Δ7d
-8.3
Δ21d
-51.7
Why this grade
Composite grade F. Momentum 7.4 / Value 40.6 / Sentiment 44.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$622.98M
Beta
2.68
Shares Out
107.23M
P/E (TTM) · Derived
-2.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.37
Rev YoY
-100.0%
EPS YoY
-9.1%
Gross Margin
+55.0%
Op Margin
-
Net Debt
-$167.91M
Current Ratio
13.82
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data